Plasma homocysteine concentration is not associated with activated protein C resistance in patients investigated for hypercoagulability

Summary

Homocysteine and activated protein C (aPC) resistance are known risk factors for thromboembolism, but how elevated homocysteine influences thrombogenicity is not fully understood. The possibility that homocysteine may exert a prothrombotic effect by inducing aPC resistance has been addressed, with conflicting conclusions. The aim of this study is to evaluate the possible relationship of serum homocysteine concentration to aPC resistance in a cohort of patients investigated for hypercoagulability. Laboratory records from 1011 consecutive patients referred to the Haemostasis Laboratory at the Health Sciences Centre (Winnipeg, Canada) were reviewed from February 1997 to November 2002. Homocysteine levels, normalized aPC sensitivity ratio (aPCSR), and Factor V Leiden genotype were recorded for all 1011 patients. 394 patients had aPC-SR determined by mixing the patient plasma in 4 parts FV deficient plasma (FV-deficient-mix assay), and 617 patients had aPC-SR calculated without mixing (neat assay). Homocysteine did not significantly influence the aPC-SR when using the FV deficient assay. When aPC-SR was measured using the neat assay, homocysteine was found to correlate inversely with the degree of aPC resistance. The mean aPC-SR of FV Leiden-negative subjects measured using the neat assay was substantially lower than the expected normalized value of 1.0 that was obtained when aPC-SR was measured with the FV-deficient-mix assay. aPC resistance is common in patients being evaluated for possible hypercoagulability. In these patients, elevated plasma homocysteine levels is not associated with aPC resistance regardless of FV Leiden genotype suggesting that this is not the mechanism by which homocysteine exerts a prothrombotic effect.

Keywords

Homocysteine - APC resistance - thrombosis

• References

• 1 Welch GN, Loscalzo J. Homocysteine and Atherothrombosis. N Engl J Med 1998; 338: 1042-50.
• 2 Homocysteine Studies Collaboration. Homocysteine and risk of ischaemic heart disease and stroke. A meta-analysis. JAMA 2002; 288: 2015-22.
• 3 den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
• 4 den Heijer M, Rosendaal FR, Blom HJ. et al. Hyperhomocysteinemia and venous thrombosis; a meta-analysis. Thromb Haemost 1998; 80: 874-7.
• 5 Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from meta-analysis. BMJ 2002; 325: 1202-8.
• 6 Khajuria A, Houston DS. Pathogenesis of hyperhomocysteinemia – new insights. Hematology 2001; 06: 217-30.
• 7 Svensson P, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
• 8 Ridker PM, Hennekens CH, Selhub J. et al. Interrelation of Hyperhomocysteinemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
• 9 Bernardi F, Faioni EM, Castoldi E. et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90: 1552-57.
• 10 de Visser MC, Rosendaal ER, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-76.
• 11 Tirado I, Mateo J, Oliver A. et al. Patients with venous thromboembolism have a lower APC response than controls. Should this be regarded as a continuous risk factor for venous thrombosis?. Haematologica 1999; 84: 470-2.
• 12 Graf LL, Welsh CH, Qamar Z. et al. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden. Am J Clin Pathol 2003; 119: 52-60.
• 13 Clark P, Walker I. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-73.
• 14 Undas A, Williams EB, Butenas S. et al. Homocysteine inhibits inactivation of factor Va by activated protein C. J Biol Chem 2001; 276: 4389-97.
• 15 Lentz SR, Piegors DJ, Fernandez JA. et al. Effect of hyperhomocysteinaemia on protein C activation and activity. Blood 2002; 100: 2108-12.
• 16 Jacobsen DW, Gatautis VJ, Green R. et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamine and folate concentrations in healthy subjects. Clin Chem 1994; 40: 873-81.
• 17 Fiskerstrand T, Refsum H, Kvalheim G. et al. Homocysteine and other thiols in plsma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-71.
• 18 Kirschbaum NE, Foster PA. The polymerase chain reaction with sequence specific primers for the detection of the factor V mutation associated with activated protein C resistance. Thomb Haemost 1995; 74: 874-8.
• 19 Clarke R, Woodhouse P, Ulvik A. et al. Variability and determinants of total homocysteine concentrations in plasma in an elderly population. Clin Chem 1998; 44: 102-7.
• 20 Laffan MA, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis 1996; 07: 761-5.
• 21 Henkens CM, Bom VJ, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost 1995; 74: 1198-9.
• 22 Viganò S, Mannucci PM, D’Angelo A. et al. Protein C antigen is not an acute phase reactant and is often high is ischemic heart disease and diabetes. Thromb Haemost 1984; 52: 263-6.
• 23 Aboud MR, Ma DD. Increased incidence of venous thrombosis in patients with shortened activated partial thromboplastin times and low ratios for activated protein C resistance. Clin Lab Haematol 2001; 23: 411-6.
• 24 Clark P, Walker I. The phenomenon known as acquired activated protein C resistance. Br J Haematol 2001; 115: 767-73.
• 25 Høibraaten E, Mowinckel MC, de Ronde H. et al. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double blind, placebo controlled trial. Br J Haematol 2001; 115: 415-20.
• 26 Soria JM, Almasy L, Souto JC. et al. A new locus on chromosome 18 that influences normal variation in activated protein C resistance phenotype and factor VIII activity and its relation to thrombosis susceptibility. Blood 2003; 101: 163-7.
• 27 Wang H, Yoshizumi M, Lai K. et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not by cysteine. J Biol Chem 1997; 272: 25380-83.
• 28 Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 251: 669-76.
• 29 Khajuria A, Houston DS. Induction of monocyte tissue factor expression by homocysteine: a possible mechanism for thrombosis. Blood 2000; 96: 966-72.